House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Cardiology

Heart failure — 2026 ESC guidelines

ESC · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This focused summary uses the official ESC 2026 heart-failure recommendation slides. The update reorganizes ejection-fraction phenotypes and emphasizes foundational medical therapy, individualized decongestion, early follow-up and multidisciplinary care. Reduced and preserved ejection fraction require clinical diagnosis rather than an isolated measurement; the complete diagnostic algorithms and detailed treatment eligibility remain in the full guideline.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Confirm heart failure and evaluate its cause

  • In suspected heart failure, obtain natriuretic peptides, ECG, chest radiography and transthoracic echocardiography. Interpret natriuretic peptides with age, obesity and other influences; echo helps confirm the diagnosis, classify phenotype and identify the cause. [1]
  • Screen for comorbidity with blood count, kidney function including eGFR and UACR, electrolytes, liver and thyroid function, HbA1c, lipids, and iron status using ferritin and transferrin saturation. [1]
  • If cardiac amyloidosis is suspected, the recommended initial tests include serum and urine immunofixation, serum free light chains and DPD/PYP/HMDP bone scintigraphy. [1]

Initiate and maintain phenotype-appropriate treatment

  • For symptomatic heart failure regardless of ejection fraction, recommend dapagliflozin or empagliflozin and an MRA. The MRA recommendation distinguishes steroidal MRAs for HFrEF from steroidal or non-steroidal MRAs for HFpEF. [1]
  • For stable symptomatic HFrEF, recommend a beta-blocker and an ACE inhibitor or ARNI. Switching an ACE inhibitor or ARB to an ARNI is recommended; an ARB is an alternative when ACE inhibitor or ARNI cannot be tolerated. [1]
  • Use loop diuretics with doses adjusted to volume status for congestion. Titrate foundational therapy at least every 1–2 weeks, guided by symptoms, vital signs and laboratory results, toward effective target or tolerated doses. [1]
  • Continue foundational therapy at the highest tolerated doses when symptoms resolve or ejection fraction improves. Gradual withdrawal is only a may-consider option for highly selected patients after treatment of a reversible cause, with complete normalization of LV function, volume and natriuretic peptides, and frequent clinical, laboratory and imaging surveillance. [1]
  • In symptomatic HFrEF with LVEF at most 40% despite optimal foundational therapy, consider digoxin or digitoxin to reduce hospitalizations. In symptomatic HFpEF, ACE inhibitor, ARB or ARNI may be considered to reduce hospitalization risk. [1]

Assess selected patients for device treatment

  • An ICD is recommended for primary prevention in ischaemic HFrEF with NYHA II–III symptoms and LVEF at most 35% despite at least 3 months of optimal therapy, excluding MI in the preceding 40 days, when good functional survival beyond 1 year is expected. Similar non-ischaemic disease is a consider recommendation. [1]
  • CRT is recommended for symptomatic HFrEF with LVEF at most 35% despite optimal therapy, sinus rhythm, LBBB and QRS at least 150 ms. CRT is not recommended with QRS below 130 ms unless high-degree AV block creates a pacing indication; other device pathways require the full eligibility criteria. [1]

Treat decompensation and arrange early reassessment

  • For decompensated heart failure with fluid overload, give intravenous loop diuretics. Consider short-term intravenous acetazolamide or oral hydrochlorothiazide in patients previously treated with loop diuretics to improve decongestion. [1]
  • Give oxygen for saturation below 90% or arterial oxygen pressure below 60 mmHg. Consider prompt non-invasive ventilation for respiratory distress with respiratory rate above 25/min and saturation below 90%; intubate for persistent progressive respiratory failure despite oxygen or non-invasive ventilation. [1]
  • Initiate an SGLT2 inhibitor in hospital after initial stabilization of decompensated heart failure. Evaluate carefully for persistent congestion before discharge, and use rapid initiation and titration of foundational therapy with frequent visits during the first 6 weeks after hospitalization. [1]
  • Routine opiates are not recommended in decompensated heart failure, apart from severe or intractable pain or anxiety. Vasopressors, preferably norepinephrine, may be considered in cardiogenic shock to support blood pressure and organ perfusion. [1]
  • Use a multidisciplinary shock team when considering temporary mechanical support. Temporary support is not recommended indiscriminately for MI-related shock, and an intra-aortic balloon pump is not recommended for unselected cardiogenic shock. [1]

Address comorbidities and advanced disease

  • Recommend early advanced-heart-failure centre consultation for motivated patients with advanced disease or risk of progression who have no absolute contraindication to transplantation or durable mechanical support, so candidacy can be evaluated. [1]
  • For symptomatic HFrEF with iron deficiency, recommend intravenous iron to improve symptoms and quality of life; it should also be considered to reduce heart-failure hospitalization. [1]
  • Consider semaglutide or tirzepatide for symptomatic heart failure with LVEF at least 45% and BMI at least 30 kg/m², regardless of diabetes status, to reduce weight and improve exercise capacity and quality of life. [1]
  • Adaptive servo-ventilation is not recommended for HFrEF with predominantly central sleep apnoea because mortality risk increases. NSAIDs and COX-2 inhibitors are also not recommended in heart failure because they increase worsening and hospitalization. [1]
  • Provide multidisciplinary management, self-management education and adherence support. Recommend individualized exercise for stable patients unless contraindicated. Advanced disease warrants goals-of-care conversations and access to integrated palliative care. [1]
  • Arrange preconception counselling for people with heart failure. During pregnancy, ACE inhibitors, ARBs, ARNIs, MRAs, ivabradine and SGLT2 inhibitors are not recommended because of fetal risks; beta-blocker selection and maternal–fetal monitoring need the pregnancy-specific pathway. [1]

Limitations and use

  • This summary covers selected official recommendation slides. Complete diagnostic algorithms, cutoffs and practical prescribing guidance are not reproduced.
  • This selected summary does not supply complete initiation doses, renal/potassium thresholds, washout periods, contraindications, device selection, cardiogenic-shock management, or pregnancy regimens. Apply the full guideline and patient-specific prescribing guidance.
  • The 2026 phenotype terminology differs from earlier ESC editions. Do not combine older phenotype labels with the new treatment table without checking the current definitions; an ejection-fraction number alone does not diagnose heart failure.
  • This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Heart failure — 2026 ESC guidelines — focused recommendation source

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
ESC
Resource type
Clinical guideline · House clinical summary

Earlier House summaries: chronic heart failure in adults esc

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Confirm heart failure and evaluate its cause
  • Initiate and maintain phenotype-appropriate treatment
  • Assess selected patients for device treatment
  • Treat decompensation and arrange early reassessment
  • Address comorbidities and advanced disease
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House